Point72 Asset Management increased stake in Tricida, Inc. By Investing.com

On the 23rd of March, Point72 Asset Management bought 1.3 million Tricida , Inc. (NASDAQ:) shares for $6.6 million at an average price of $5.01 per share.
Shares of Tricida, Inc. are down -5.39% since the transaction.

Point72 Asset Management’s holding in Tricida, Inc. increased to about 2.5 million shares with the purchase.

Point72 Asset Management first bought Tricida, Inc. stock in the fourth quarter of 2018.
Point72 Asset Management also owns AstraZeneca PLC ADR (NASDAQ:), Merck (MRK), Eli Lilly & Co (NYSE:) and Chinook Therapeutics, Inc. (KDNY).
Tricida, Inc. is its number thirty nine position by number of shares and market value among biotechnology & life sciences stocks.

Other investors who also added to their Tricida, Inc. shares include Citigroup (NYSE:) and Millennium Management.
In contrast, the T. Rowe Price Equity Income Fund and Squarepoint Ops reduced TCDA shares.

Point72 Asset Management has also recently reduced their share in VYNE Therapeutics INC (VYNE) and MacroGenics, Inc. (NASDAQ:).
The total value of the shares sold is estimated at around $53 million.

In addition, Point72 Asset Management established new holdings in CytomX Therapeutics, Inc. (NASDAQ:) and AnaptysBio, Inc. (NASDAQ:).
Point72 Asset Management also added to their share in Affimed N.V. (NASDAQ:), Kadmon Holdings Inc (NASDAQ:), Bicycle Therapeutics plc (NASDAQ:) and Mereo BioPharma Group plc (MREO).
The total value of the shares bought is estimated at around $123 million.

Point72 Asset Management also reduced their share in Syros Pharmaceuticals, Inc. (NASDAQ:), American Eagle Outfitters Inc (NYSE:), Childrens Place Inc (PLCE), Cytokinetics Inc (NASDAQ:), ANGI Homeservices Inc (NASDAQ:), Dave & Busters Entertainment Inc (NASDAQ:), Otonomy, Inc. (NASDAQ:), Calithera Biosciences, Inc. (CALA), Chiasma Inc (NASDAQ:) and Fulcrum Therapeutics, Inc. (NASDAQ:).
The total value of the shares sold is estimated at around $58 million.

In addition, Point72 Asset Management established new holdings in Curis Inc (CRIS), Miragen Therapeutics Inc (NASDAQ:), Aeglea BioTherapeutics, Inc. (AGLE), Hims & Hers Health, Inc. (HIMS) and Paya Holdings Inc. (PAYA).
Point72 Asset Management also added to their share in Alliance Data Systems Corp (NYSE:), BioCryst (NASDAQ:) Pharmaceuticals Inc (BCRX), BGC Partners Inc (NASDAQ:), Revolve Group Inc (NYSE:) and Acorda Therapeutics Inc (NASDAQ:).
The total value of the shares bought is estimated at around $270 million.